A comparative study of functional assays for tissue factor pathway inhibitor using normal plasma and clinical samples

Blood Coagulation and Fibrinolysis

Volumn 11, Issue 4, 2000, Pages 327-333

  Adams, M J ^a   Oostryck, R ^a  

^a CURTIN UNIVERSITY   (Australia)

Author keywords

Functional assay; Thrombosis; Tissue factor pathway inhibitor

Indexed keywords

HEPARIN; TISSUE FACTOR PATHWAY INHIBITOR;

ADULT; ARTICLE; ASSAY; BLOOD CLOTTING; BLOOD SAMPLING; CONTROLLED STUDY; DIABETES MELLITUS; HEPARINIZATION; HUMAN; MAJOR CLINICAL STUDY; PLASMA; PRIORITY JOURNAL; STANDARDIZATION; THROMBOSIS;

BIOLOGICAL ASSAY; CORONARY DISEASE; DIABETES MELLITUS; HEPATITIS; HUMANS; LIPOPROTEINS; REFERENCE STANDARDS; SENSITIVITY AND SPECIFICITY; VENOUS THROMBOSIS;

EID: 0034042885     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-200006000-00003     Document Type: Article

References (24)

1. 1. Hubbard AR, Weller LJ, Gray E. Measurement of tissue factor pathway inhibitor in normal and postheparin plasma. Blood Coal Fibrinol 1994; 5: 819-823.
2. 2. Jeske W, Hoppensteadt D, Fareed J, Barnes E. Measurement of functional and immunologic levels of tissue factor pathway inhibitor. Some methodologic considerations. Blood Coag Fibrinol 1995; 6: S73-S80.
3. 3. Bognacki J, Hammelburger J. Functional and immunologic methods for the measurement of human tissue factor pathway inhibitor. Blood Coag Fibrinol 1995; 6: S65-S72.
4. 4. Lindahl AK, Jacobsen PBJ, Sandset PM, Abildgaard U. Separation of tissue factor pathway inhibitor by heparin affinity: plasma from cancer patients and postheparin plasma contain increased amounts of fraction with high anticoagulant activity. Blood Coal Fibrinol 1991; 2: 713-721.
5. 5. Lindahl AK, Abildgaard U, Larsen ML, Staalesen R, Hammer AKG, Sandset PM, et al. Extrinsic pathway inhibitor (EPI) released to the blood by heparin is a more powerful coagulation inhibitor than is recombinant EPI. Thromb Res 1991; 62: 607-614.
6. 6. Wun TC, Huang MD, Kretzmer KK, Palmier MO, Day KC, Bulock JW, et al. Immunoaffinity purification and characterisation of lipoprotein associated coagulation inhibitors from Hep G2 hepatoma, change liver and SK hepatoma cells. J Biol Cbem 1990; 265: 16096-16101.
7. 7. Hjort PF. Intermediate reactions in the coagulation of blood with tissue thromboplastin. Scand J Clin Lab Invest 1957; 9: 1-182.
8. 8. Adams MJ, Dunstan RA, Oostryck R. Interference by lupus anticoagulant in a functional assay for tissue factor pathway inhibitor. Thromb Res 1995; 80: 435-440.
9. 9. Warr TA, Rao LVM, Rapaport SI. Human plasma extrinsic pathway inhibitor activity: II plasma levels in disseminated intravascular coagulation and hepatocellular disease. Blood 1989; 74: 994-998.
10. 10. Warr TA, Warn-Cramer BJ, Rao LVM, Rapaport SI. Human plasma extrinsic pathway inhibitor activity: I. standardisation of assay and evaluation of physiologic variables. Blood 1989; 74: 201-206.
11. 11. Sandset PM, Larsen ML, Abildgaard U, Lindahl AK, Ødegaard OR. Chromogenic substrate assay of extrinsic pathway inhibitor (EPI): levels in the normal population and relation to cholesterol. Blood Coag Fibrinol 1991; 2: 425-433.
12. 12. Adams MJ, Dunstan RA, Oostryck R. Comparison of two functional assays for tissue factor pathway inhibitor. In: Proceedings of the 28th Annual Scientific Meeting of the Haematology Society of Australia; Perth, Australia, 19-22 September 1994.
13. 13. Berrettini M, Malaspina M, Parise P, Lucarelli G, Kisiel W, Nenci GG. A simple chromogenic substrate assay of tissue factor pathway inhibitor activity in plasma and serum. Am J Clin Pathol 1995; 103: 391-395.
14. 14. Rapaport SI. Inhibition of factor VIIa/tissue factor-induced blood coagulation: with particular emphasis upon a factor Xa-dependent inhibitory mechanism. Blood 1989; 73: 359-365.
15. 15. Bajaj MS, Rana SV, Wysolmerski RB, Bajaj SB. Inhibition of the FVIIa-tissue complex is reduced in patients with disseminated intravascular coagulation but not in patients with severe hepatocellular disease. J Clin Invest 1987; 79: 1874-1878.
16. 16. Sandset PM, Abildgaard U, Larsen ML. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res 1988; 50: 803-813.
17. 17. Andersson TR, Bell H, Sandset PM, Ødegaard OR, Aamodt LM. New coagulation inhibitor levels in pneumonia, disseminated intravascular coagulation and liver disease (Abstract). Thromb Haemost 1987; 58: 305A.
18. 18. Warshawsky I, Broze GJ, Schwartz AL. The low density lipoprotein receptor-related protein mediates the cellular degradation of tissue factor pathway inhibitor. Proc Natl Acad Sci USA 1994; 91: 6664-6668.
19. 19. Sandset PM, Høgevold HE, Lyberg T, Andersson TR, Abildgaard U. Extrinsic pathway inhibitor in elective surgery: a comparison with other coagulation inhibitors. Thromb Haemost 1989; 62: 856-860.
20. 20. Lindahl AK, Abildgaard U, Stokke G. Extrinsic pathway inhibitor after heparin injection: increased response in cancer patients. Thromb Res 1990; 59: 651-656.
21. 21. Lindahl AK, Sandset PM, Abildgaard U. The present status of tissue factor pathway inhibitor. Blood Coag Fibrinol 1992; 3: 439-449.
22. 22. Østergaard P, Nørdfang O, Petersen LC, Valentin S, Kristensen, H. Is tissue factor pathway inhibitor involved in the antithrombotic effect of heparins? Haemostasis 1993; 23: 107-111.
23. 23. Hansen JB, Huseby KR, Huseby NE, Ezban M, Nordøy A. Tissue factor pathway inhibitor in complex with low density lipoprotein isolated from human plasma does not possess anticoagulant function in tissue factor induced coagulation in vitro. Thromb Res 1997; 5: 413-425.
24. 24. Rapaport SI, Rao LVM. Initiation and regulation of tissue factor-dependent blood coagulation. Arterioscler Thromb 1992; 12: 1111-1121.